Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pharma company reaches $2.2B settlement in Zantac lawsuits
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer.
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
GSK says $2.2bn settlement resolves most Zantac litigation
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there will be "no changes to GSK's growth agenda or investment plans for R&D as a result."
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
FiercePharma
2d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
2d
on MSN
UK property market strengthens, but renters face tighter squeeze; GSK’s shares surge after $2.2bn Zantac settlement – business live
Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Dems shut down AZ office
How to help Milton victims
Oklahoma mass shooting
Releases medical report
Requests military aircraft
Airstrikes hit ISIS camps
Mr. Bungle ex-member guilty
Gators displaced by Milton
Admonishes Black men
Gets Walk of Fame star
Files suit against Virginia
Expands sanctions on Iran
Russia cements ties with Iran
Dodgers advance to NLCS
CA rejects SpaceX plan
To close 444 stores
Carne asada drug bust
Fidelity data breach
S&P 500, Dow hit records
US consumer sentiment slips
To cut workforce by 10%
Gets 2 years for role in riot
Loses bid to get on PA ballot
US producer prices flat
Adds 8 new destinations
Drug for hemophilia approved
JPMorgan says soft landing
Assets hit $11.5 trillion
Calls for relief funding
Related topics
GSK
GlaxoSmithKline
Inflation
United States
Ranitidine
Feedback